Welcome back to Alpha Stocks Daily 👋
Yesterday we dug into an AI-data play with a dilution catch. Today we're in a completely different corner of the market — healthcare diagnostics — with a stock that's quietly been one of 2026's best performers, and a setup that's more of a cautionary tale than a green light.
Today's ticker: CareDx ($CDNA) — a ~$2.5B precision-medicine company that runs the genomic-surveillance testing that keeps organ-transplant patients alive. The business is real, the turnaround is real, and the chart is stunning. But when a stock is up ~130% on the year and trading above the average analyst target, the job isn't to cheerlead — it's to figure out whether there's anything left on the table.
Let's get into it. 👇
TL;DR
The bull case: A genuine turnaround — Q2 revenue +52% to $132M, raised full-year guidance, newly profitable, and a fresh push into specialty oncology.
The catch: At ~$50, CDNA trades above its ~$48 average price target; recent profits were flattered by one-time gains; and multiple directors sold millions into the rally.
What to watch: The stock is stretched far above its moving averages. Bulls need the Street-high oncology case ($60–$64) to play out; bears point to a consensus that's already been met.
📊 The Wall Street Consensus
Analysts like the business but are split on the price after the run. The consensus is a "Moderate Buy" from 7 firms — but the makeup matters: roughly 1 Strong Buy, 2 Buy, and 4 Hold, with an average 12-month target near $48.
Firm | Rating | Price Target | Note |
|---|---|---|---|
Craig-Hallum | Buy (upgrade) | $64 | Upgraded Aug 3 — "guidance feels conservative" |
BTIG | Buy | $60 | Raised from $45 (Aug 6) |
HC Wainwright | Neutral | $46 | Valuation-cautious (Jul 31) |
Street average (7 firms) | Moderate Buy | ~$48 | 1 Strong Buy · 2 Buy · 4 Hold |
Read this carefully: at ~$50, the stock is already trading at or above the average target. That's the opposite of a "room to run" setup — the market has priced in the good news. The only meaningfully bullish targets ($60–$64) are betting the new oncology business and "conservative" guidance drive the next leg. Several analysts sit at Hold specifically on valuation and non-recurring tailwinds (more on that below).
🏢 Behind the Ticker: How CareDx Makes Money
CareDx is the surveillance backbone of the U.S. transplant system. Its edge is proprietary donor-derived cell-free DNA (dd-cfDNA) testing that flags organ rejection weeks before a biopsy would — and because transplant patients need lifelong monitoring, the revenue is sticky and recurring. The portfolio:
Testing Services (the core): AlloSure (dd-cfDNA) and AlloMap (gene-expression) for kidney, heart, and lung transplants. This is ~76% of revenue and grew 61% YoY last quarter.
Patient & Digital Solutions: Care-management and EHR-integrated software (Ottr, TxAccess) used across 170+ transplant centers — workflow lock-in.
Specialty Oncology (new): In July, CareDx acquired Naveris, adding the NavDx blood test for molecular residual disease in HPV-driven head/neck and anal cancers — a brand-new growth vector beyond transplant.
Two important updates the old thesis misses: CareDx sold its lab-products business to focus the company, and it's pushing a cell-therapy pipeline (AlloCell, AlloHeme). Non-GAAP gross margin ran near 74% last quarter — genuinely high-quality economics.
🌍 Macro, Industry & Policy
The tailwind is real: healthcare is shifting toward non-invasive liquid-biopsy diagnostics over expensive, invasive procedures, and CareDx is a proven, cost-saving option.
The risk is equally real and specific: ~50% of CareDx's testing-services revenue comes from Medicare (46–53% over recent years). That makes Medicare coverage decisions (LCDs from contractors like MolDX) the single biggest swing factor on the top line. The recent news here is actually positive — management said finalized Medicare coverage supports transplant surveillance and let them remove a previously expected ~$7.5M headwind — but the structural dependence on one payer never goes away.
📰 Recent News: The Q2 Blowout (and the fine print)
On July 30, CareDx reported a monster Q2: revenue $132M (+52% YoY), testing-services revenue +61%, and testing volume up 17% to ~58,000. Management raised full-year 2026 guidance to $490M–$500M (from $447M–$465M) and adjusted EBITDA to $66M–$78M. The stock gapped up and never looked back.
The fine print that matters: the eye-popping $111M net income ($2.07/share) included a one-time ~$113M gain from selling the lab-products business — that's not operating profit. The quarter also included $15.6M of out-of-period revenue. Strip those out and the underlying picture is strong but far more normal: adjusted EBITDA of $25M (19% of revenue). This is why sharp analysts are calling the results "solid, but flattered by non-recurring tailwinds."
🕵️ Follow the Money
Insiders: Not a great look — multiple directors cashed out millions of dollars in early August, right after the run-up. That's real selling into strength, not routine housekeeping.
Institutions: CareDx is heavily institutionally owned (commonly cited around 90–95% of the float), with index giants like BlackRock and Vanguard among the largest holders. Note also a modest dilution drip — an ~$80M ESOP shelf and an expanded equity-incentive plan (~3% of shares).
Congress: No notable disclosed Congressional trading in the stock.
📊 The Charts: Stretched, Not Cheap
Context is everything here. CDNA has gone from a 52-week low of $12.37 to a high of $53.67 — a ~130% YTD move — and now trades near $50, far above its 50-day (~$39) and 200-day (~$27) moving averages. That's a powerful uptrend, but it's extended; RSI has been running hot.
Immediate resistance: ~$51 → the $53.67 all-time high
First support: ~$45–$47 (post-breakout shelf)
Structural support: ~$38–$40 (prior gap / 50-day area)
The setup: This is a momentum name, not a value entry. Chasing ~$50 into a consensus target of ~$48 is poor risk/reward; a disciplined trader watches for either a confirmed breakout above $53.67 (with the oncology story as fuel) or a pullback toward the $45 shelf.
⚠️ Risks to Respect
Valuation — trading above the average target after a ~130% run; limited margin for error.
One-time-flattered earnings — the $113M gain and out-of-period revenue inflate the headline numbers.
Medicare concentration — ~half of testing revenue rides on Medicare coverage decisions.
Insider selling — directors reducing exposure into the highs.
Integration risk — Naveris/oncology is a new, unproven leg that has to deliver to justify the bull case.
🎯 The Bottom Line
CareDx is a legitimately excellent business having a legitimately great year — high-margin, recurring, mission-critical testing, now with an oncology growth option on top. But "great company" and "great entry" are not the same thing. After a ~130% run, the stock sits above the average price target, its blowout profit leaned on one-time items, and insiders have been selling. The bull case ($60–$64) rests entirely on the next story — specialty oncology and "conservative" guidance — actually compounding. The bear case is simpler: the easy money's been made.
What we're watching next: whether $53.67 breaks with volume, how the Naveris oncology ramp trends, and the Q3 report (expected late October/early November).
Trade smart, size your risk, and we'll see you tomorrow. 🔬
Disclaimer: Alpha Stocks Daily is for educational and informational purposes only and is not financial, investment, or trading advice. We are not registered investment advisors, and nothing here is a recommendation to buy or sell any security. Data is sourced from public reports and believed accurate as of publication but is not guaranteed. Always do your own research and consult a licensed professional before investing. Past performance does not guarantee future results.